Heart failure (HF) has emerged as a major epidemic and a significant public health burden, associated with considerable morbidity and mortality [1]. Parameters specific for HF such as NYHA class and left ventricle ejection fraction are important predictors of clinical outcome in HF [2], patients with HF typically have multiple comorbid conditions that complicate management and adversely affect clinical outcome [3]. The impact of comorbid burden can be assessed by the Carlson comorbidity index (CCI), a validated score to estimate mortality in patients with multiple comorbidities [4].
